Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Seed-based System for Cost-Effective Production of Vaccine Against Chronic Respiratory Disease in Chickens
  • +2
  • Imran Khan,
  • Peyman Habibi,
  • Madiha Saeed,
  • Ayesha Haq,
  • Yao Shi
Imran Khan
University of Pennsylvania

Corresponding Author:[email protected]

Author Profile
Peyman Habibi
University of Pennsylvania Perelman School of Medicine
Author Profile
Madiha Saeed
International Islamic University
Author Profile
Ayesha Haq
International Islamic University
Author Profile
Yao Shi
University of Pennsylvania
Author Profile

Abstract

The production of vaccines in plant cells, termed as plant-made pharmaceuticals or molecular farming, is a promising technology. Compared to mammalian cell lines, like HEK293 and CHO as established platform, plants can be grown cost effectively on a large-scale without necessitating any sophisticated technologies. An innovative application of this alternative system is the production of vaccines in edible tissues that can be consumed orally to deliver protein antigen without any further processing. In this project we reported stable expression of TM-1 protein of MG as vaccine candidate antigen against Chronic Respiratory Disease (CRD) in wheat seeds tissues. The molecular and Immunoblotting analysis confirmed the integration of recombinant protein of 41.8 kDa with expression level of 1.03mg/g DW in endosperm tissues. When orally delivered, the plant made vaccine were highly effective in terms of developing antibodies in chicken without any detectable weight loss. Two doses of orally delivered plant-made TM-1 vaccine candidate elicited an immune response and protective effect against MG virus challenge at the level comparable to commercially available inactivated vaccine against CRD. Our study demonstrated that plant-made vaccines are not only safe but also similarly effective to commercially available vaccines.
13 Mar 2021Submitted to Biotechnology Journal
16 Mar 2021Submission Checks Completed
16 Mar 2021Assigned to Editor
22 Mar 2021Reviewer(s) Assigned
17 May 2021Editorial Decision: Revise Major